The Adipose Tissue-Derived Secretome (ADS) in Obesity Uniquely Induces L-Type Amino Acid Transporter 1 (LAT1) and mTOR Signaling in Estrogen-Receptor-Positive Breast Cancer Cells

被引:11
|
作者
Thompson, Chelsea [1 ,2 ]
Rahman, M. Motiur [2 ,3 ,4 ]
Singh, Soudamani [2 ,3 ,4 ]
Arthur, Subha [2 ,3 ,4 ]
Sierra-Bakhshi, Cecilia [1 ,2 ]
Russell, Rebecca [2 ,5 ]
Denning, Krista [2 ,5 ]
Sundaram, Uma [2 ,3 ,4 ]
Salisbury, Travis [1 ,2 ,3 ,4 ]
机构
[1] Marshall Univ, Joan C Edwards Sch Med, Dept Biomed Sci, Huntington, WV 25755 USA
[2] Marshall Univ, Joan C Edwards Sch Med, Appalachian Ctr Cellular Transport Obes Related D, 1600 Med Ctr Dr, Huntington, WV 25755 USA
[3] Marshall Univ, Joan C Edwards Sch Med, Dept Clin & Translat Sci, 1600 Med Ctr Dr, Huntington, WV 25701 USA
[4] Marshall Univ, Joan C Edwards Sch Med, Appalachian Clin & Translat Sci Inst, 1600 Med Ctr Dr, Huntington, WV 25701 USA
[5] Marshall Univ, Joan C Edwards Sch Med, Dept Pathol, Cabell Huntington Hosp Lab, Huntington, WV 25701 USA
基金
美国国家卫生研究院;
关键词
breast cancer; obesity; LAT1; leucine; mTOR; GROWTH; LEUCINE; METABOLISM; MECHANISMS; OVERWEIGHT; HETERODIMERS; 4F2HC/CD98; EXPRESSION; MDA-MB-231; PATHWAY;
D O I
10.3390/ijms22136706
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Obesity increases the risk of postmenopausal breast cancer (BC). This risk is mediated by obesity-induced changes in the adipose-derived secretome (ADS). The pathogenesis of BC in obesity is stimulated by mTOR hyperactivity. In obesity, leucine might support mTOR hyperactivity. Leucine uptake by BC cells is through L-Type Amino Acid Transporter 1 (LAT1). Our objective was to link obesity-ADS induction of LAT1 to the induction of mTOR signaling. Lean- and obese-ADS were obtained from lean and obese mice, respectively. Breast ADS was obtained from BC patients. Estrogen-receptor-positive BC cells were stimulated with ADS. LAT1 activity was determined by uptake of H-3-leucine. The LAT1/CD98 complex, and mTOR signaling were assayed by Western blot. The LAT1 antagonists, BCH and JPH203, were used to inhibit LAT1. Cell migration and invasion were measured by Transwell assays. The results showed obese-ADS-induced LAT1 activity by increasing transporter affinity for leucine. Consistent with this mechanism, LAT1 and CD98 expression were unchanged. Induction of mTOR by obese-ADS was inhibited by LAT1 antagonists. Breast ADS from patients with BMIs > 30 stimulated BC cell migration and invasiveness. Collectively, our findings show that obese-ADS induction of LAT1 supports mTOR hyperactivity in luminal BC cells.
引用
收藏
页数:13
相关论文
共 32 条
  • [31] Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer
    Kaira, Kyoichi
    Oriuchi, Noboru
    Imai, Hisao
    Shimizu, Kimihiro
    Yanagitani, Noriko
    Sunaga, Noriaki
    Hisada, Takeshi
    Kawashima, Osamu
    Kamide, Yosuke
    Ishizuka, Tamotsu
    Kanai, Yoshikatsu
    Nakajima, Takashi
    Mori, Masatomo
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2010, 1 (05) : 799 - 808
  • [32] Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study.
    Furuse, Junji
    Ikeda, Masafumi
    Ueno, Makoto
    Furukawa, Masayuki
    Morizane, Chigusa
    Takehara, Tetsuo
    Nishina, Tomohiro
    Todaka, Akiko
    Okano, Naohiro
    Hara, Kazuo
    Nakai, Yousuke
    Ohkawa, Kazuyoshi
    Sasaki, Takashi
    Sugimori, Kazuya
    Yokoyama, Naoyuki
    Yamamoto, Kouji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 494 - 494